Dear Editor: There is no doubt now that the use of botulinum toxin (BoNT) in aesthetics has been a revolution for the noninvasive treatment of patients. In the last several decades, the use of BoNT has changed from fixed doses delivered at fixed time intervals into fixed anatomical sites, all of which were required for
Dear Editor: We are writing to highlight the interesting but little explored interaction between sleep and melasma, a common dermatological disease that causes a major impact on several areas of the lives of individuals with the condition. Melasma causes skin hyperpigmentation and is characterized by symmetric hypermelanosis of sun-exposed skin represented by brown macules and
Dear Editor: An African American man in his 50s presented with a one-year history of a pruritic rash on his anterior shins. His past medical history was significant for a recent diagnosis of diabetes. A physical examination revealed scattered, atrophic, pink/purple papules and plaques with reticular pigment on the bilateral anterior lower legs (Figure 1).
Dear Editor: Tofacitinib is a Janus kinase (JAK) 1/3 inhibitor that has been approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. An increasing number of studies have demonstrated the efficacy of tofacitinib in treatment of alopecia areata (AA).1–6 Treatment duration in these studies
by Andrew J. Krispinsky, MD; Polina V. Rzepka, MD; Farrukh Awan, MD; and Benjamin H. Kaffenberger, MD Drs. Krispinsky, Rzepka, and Kaffenberger are with the Division of Dermatology and Dr. Awan is with the Division of Hematology— all from the Department of Internal Medicine at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio. Funding/disclosures. Dr. Awan